Literature DB >> 31872447

Pembrolizumab as a Cause of Cholangiopathy in a Patient With Metastatic Melanoma.

Laura Stuart1, Beth Lambourne2, Paul Turner3, David E J Jones4,5, Ruth Plummer2, Nicola Cresti2, Jessica K Dyson4,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31872447     DOI： 10.1002/hep.31089

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  3 in total

1.  Hepatobiliary and Pancreatic Adverse Events.

Authors:  Hao Chi Zhang; Lan Sun Wang; Ethan Miller
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Pembrolizumab-induced large duct cholangiopathy: Diagnosis and follow.up imaging.

Authors:  A Chatterjee; B K Bivas; A Gehani; S Sen
Journal:  J Postgrad Med       Date:  2021 Jan-Mar       Impact factor: 1.476

3.  Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis.

Authors:  Masaki Takinami; Akira Ono; Takanori Kawabata; Nobuaki Mamesaya; Haruki Kobayashi; Shota Omori; Kazushige Wakuda; Hirotsugu Kenmotsu; Tateaki Naito; Haruyasu Murakami; Masahiro Endo; Yoshio Kiyohara; Hirofumi Yasui; Masashi Niwakawa; Toshiaki Takahashi
Journal:  Invest New Drugs       Date:  2021-05-28       Impact factor: 3.850
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.